James F. Oliviero III
2020
In 2020, James F. Oliviero III earned a total compensation of $2.3M as President, Chief Executive Officer and Director at Checkpoint Therapeutics, a 1% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $319,300 |
|---|---|
| Salary | $515,000 |
| Stock Awards | $1,453,140 |
| Total | $2,287,440 |
Oliviero received $1.5M in stock awards, accounting for 64% of the total pay in 2020.
Oliviero also received $319.3K in non-equity incentive plan and $515K in salary.
Rankings
In 2020, James F. Oliviero III's compensation ranked 4,934th out of 13,090 executives tracked by ExecPay. In other words, Oliviero earned more than 62.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,934 out of 13,090 | 62nd |
Division Manufacturing | 2,005 out of 5,621 | 64th |
Major group Chemicals And Allied Products | 796 out of 2,254 | 65th |
Industry group Drugs | 687 out of 1,954 | 65th |
Industry Pharmaceutical Preparations | 515 out of 1,459 | 65th |
Source: SEC filing on April 30, 2021.
Oliviero's colleagues
We found one more compensation record of an executive who worked with James F. Oliviero III at Checkpoint Therapeutics in 2020.
2020
William Gray
Checkpoint Therapeutics
Chief Financial Officer
News
Checkpoint Therapeutics CEO James Oliviero's 2023 pay slips 20% to $1.6M
April 2, 2024
Checkpoint Therapeutics CEO James Oliviero's 2022 pay slips 11% to $2M
May 1, 2023
Checkpoint Therapeutics CEO James Oliviero's 2021 pay stays at $2.3M
April 29, 2022
Checkpoint Therapeutics CEO James Oliviero's 2020 pay slips 1% to $2.3M
April 30, 2021
Checkpoint Therapeutics CEO James Oliviero's 2019 pay rises 8% to $2.3M
April 24, 2020
Checkpoint Therapeutics CEO James Oliviero's 2018 pay jumps 230% to $2.1M
April 30, 2019